Join JAAGNet and Group

SIgn up for JAAGNet & the MedTech Group its FREE!!


Member Benefits:


Again signing up for JAAGNet & Group Membership is FREE and will only take a few moments!

Here are some of the benefits of Signing Up:

  • Ability to join and comment on all the JAAGNet Domain communities.
  • Ability to Blog on all the Domain communities 
  • Visibility to more pages and content at a group community level, such as Community, Internet, Social and Team Domain Community Feeds.
  • Make this your only content hub and distribute your blogs to LinkedIn, Reddit, Facebook, Twitter, WhatsApp, Messenger, Xing, Skype, WordPress Blogs, Pinterest, Email Apps and many, many more (100+) social network and feed sites. 
  • Opportunity to collaborate (soon to be  released) with various JAAGNet Business communities and other JAAGNet Network members.
  • Connect (become friends), Follow (and be Followed) and Network with JAAGNet members with similar interests.
  • Your Content will automatically be distributed on Domain and JAAGNet Community Feeds. Which are widely distributed by the JAAGNet team.

Join Us!

Gold Level Contributor
Cell therapy repairs multiple sclerosis damage and restores motor functions in mice

A cell therapy out of the University of Rochester Medical Center is in development to treat neurological diseases marked by a loss of glial cells, which are critical to preserving signals between brain cells. (CC0 Creative Commons)

Glial cells play several key roles in the central nervous system, including supplying oxygen to neurons and forming myelin—the protective, fatty substance that protects the nerve cells’ axons. In multiple sclerosis (MS), glial cells called oligodendrocytes are attacked by the immune system, causing a breakdown of myelin that disrupts the signals between nerve cells and results in a loss of motor and sensory functions.

A team of researchers at the University of Rochester Medical Center (URMC) is developing a method for regenerating myelin with progenitor glial cells. When they transplanted the cells into mouse models of MS, the cells transformed into new oligodendrocytes and restored myelin. They reported the results of the study in the journal Cell Reports.

Now, a company that was spun out of the university last year, Oscine Therapeutics, is preparing the cell therapy for human clinical trials in MS and other glial diseases, according to a statement. Oscine received an undisclosed amount of funding last year from Sana Biotechnology, a cell therapy developer backed by funding from Arch, Flagship and F-Prime.

The cell therapy got its start in the lab of Steve Goldman, M.D., Ph.D., professor of neurology and neuroscience at URMC, who led a 15-year effort to figure out how to coax stem cells into becoming glial cells. Their hope was to develop the therapy to treat progressive multiple sclerosis—a stage of the disease during which oligodendrocytes become exhausted and can no longer make myelin.

In the mouse study, Goldman and colleagues showed that after transplantation, the human glial progenitor cells migrated to damaged areas of the brain. After they created new oligodendrocytes, myelation was restored, as was motor functioning, the team reported. Goldman is the scientific founder and a shareholder in Oscine.

Much of the regenerative medicine research in MS is focused on restoring myelin, and several different approaches are under investigation. Last year, researchers from VA Maryland Health Care System and the University of Maryland reported that when they implanted stem cells with the surface protein CD34 into mouse models of MS, the cells grew into myelin-forming glial cells. Other experimental approaches to regenerating myelin include using microRNAs and reprogrammed skin cells.

San Francisco-based Atara Biotherapeutics is targeting Epstein-Barr virus (EBV), which has been shown to raise the risk of MS. The company is developing T-cell therapies targeting EBV and has started early human trials. Last year, Atara released data from a phase 1 study showing a partial improvement in MS symptoms six months following treatment with one of its EBV-targeted therapies, ATA188.

The FDA is currently reviewing Oscine’s plan to bring URMC’s glial cell therapy into clinical trials, according to the statement. The company’s researchers believe it could prove promising in other diseases marked by glial defects, too, including Huntington’s.

Originally published by
Arlene Weintraub | May 19, 2020


E-mail me when people leave their comments –

You need to be a member of JAAGNet to add comments!

Join JAAGNet

JAAGNet MedTech Feeds

American Diabetes Association - 80th Scientific Sessions - Virtual

DIA 2020 Global Annual Meeting

Ai4 2020 - Healthcare Track Exploring Artificial Intelligence in Healthcare - Las Vegas

  • Description:

    Ai4 2020 – Healthcare Track Exploring Artificial Intelligence in Healthcare

    Over two days, the Healthcare Track at Ai4 2020 brings together business leaders and data practitioners to facilitate the adoption of artificial intelligence and machine learning technology.

    With a use-case oriented approach to content, our goal is to deliver actionable insights from those working on the…

  • Created by: Kathy Jones
  • Tags: ai, healthcare, las vegas, nevada

MedTech Strategist - Innovation Summit Dublin

BIOMEDevice - Boston 2020

  • Description:

    BIOMEDevice - Boston 2020

    2,200+ industry professionals and 335+ suppliers convene in Boston — home to the nation's highest number of medical device companies — for a two-day event focused on moving medtech design projects to the next stage of development.

    BIOMEDevice lets you explore the trends driving advancements in healthcare as well as discover technologies for engineering devices for…

  • Created by: Kathy Jones
  • Tags: biomedevice, boston, north america, medtech

The MedTech Conference - Toronto

  • Description:

    The MedTech Conference

    Featuring world‑class plenary speakers, cross‑cutting educational programming, valuable networking and business development opportunities, The MedTech Conference is a must‑attend event for the industry’s prominent and most promising companies.

    Explore more than 125 companies and the popular CEOs Unplugged Stage, the Innovation Pavilion, the Patient…

  • Created by: Kathy Jones
  • Tags: medtech, toronto, canada


JAAGNet MedTech Blog Archive

See Original | Powered by elink

JAAGNet MedTech Video Playlist